News

Novo Nordisk bags drug delivery platform
Enlarge image

BusinessDenmark

Novo Nordisk bags drug delivery platform

03.05.2012 - Denmark’s Novo Nordisk has exclusively licensed Caisson's heparosan-based drug delivery to develop compounds of its drug pipeline.

Oklahoma City/Austin/Baegsvard – With the exclusive license deal, Novo Nordisk has secured a key platform to extend the life cycle of its existing drugs by simply attaching them to bio-inert sugar polymers, which cannot be degraded extra-cellularly. Under the terms of the agreement, Caisson Biotech LLC, a wholly owned subsidiary of Heparinex, L.L.C, will receive an undisclosed upfront payment from the Danish drugmaker plus fees for contract research and manufacturing. In addition, Caisson will be eligible to receive milestone payments upon achievement of certain predefined clinical, regulatory and commercial targets, plus royalties on the global sales of the therapeutic products developed under the agreement, representing a total deal value of more than $100m. 

Caisson’s drug delivery technology, who was invented by the firm’s CSO Dr. Paul DeAngelis at the University of Oklahoma, utilises heparosan, a naturally occurring sugar polymer that is stable and inert in the bloodstream, but is biodegradable inside cells for the purpose of cloaking, enlarging and/or protecting drug cargo. Heparosan can be customised with respect to polymer size and conjugation chemistry, thus increasing product half-life, reducing immunogenicity, and increasing stability. 

In contrast to PEGylation, heparosanylation shows no toxicity. Additionally, Caisson Biotech claims higher and faster water solubility, longer excretion half life and its larger flexibility concerning usage to different drug types and delivery systems.

http://www.european-biotechnology-news.com/news/news/2012-02/novo-nordisk-bags-drug-delivery-platform-for-100m.html

BusinessUK

03.03.2015 After weeks of speculation, AstraZeneca has announced its plans to spin out its early-stage antibiotic R&D. The decision marks the company’s aims to “sharpen its focus on three main therapy areas”.

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE4.64 EUR7.16%
  • FORMYCON16.89 EUR4.07%
  • BIOFRONTERA1.99 EUR3.65%

FLOP

  • HBM102.00 CHF-2.86%
  • SYNGENTA327.00 CHF-2.15%
  • STRATEC BIOMEDICAL45.12 EUR-2.10%

TOP

  • WILEX3.17 EUR48.8%
  • EVOLVA1.70 CHF18.9%
  • MEDIGENE4.64 EUR16.6%

FLOP

  • MOLOGEN5.25 EUR-14.1%
  • SANTHERA98.45 CHF-10.3%
  • 4SC0.77 EUR-9.4%

TOP

  • SANTHERA98.45 CHF2457.1%
  • WILEX3.17 EUR403.2%
  • FORMYCON16.89 EUR115.7%

FLOP

  • CYTOS0.37 CHF-86.9%
  • MOLOGEN5.25 EUR-57.4%
  • PAION2.10 EUR-55.3%

No liability assumed, Date: 04.03.2015